Putting the efficacy of candesartan cilexetil into perspective: A review of new comparative data

Journal of Human Hypertension

Volumn 14, Issue , 2000, Pages S33-S41

  Mallion, J M ^a   Baguet, J P ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

Angiotensin II AT1 receptor antagonist; Antihypertensive treatment; Candesartan cilexetil; Comparative efficacy review

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; RENIN; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; IC 50; IN VIVO STUDY; META ANALYSIS; METABOLIC DISORDER; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; RECEPTOR AFFINITY; RECURRENT DISEASE;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CATTLE; CEREBELLUM; CIRCADIAN RHYTHM; FEMALE; HEART; HUMANS; HYPERTENSION; KINETICS; LOSARTAN; MALE; MIDDLE AGED; PRODRUGS; RABBITS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN; TETRAZOLES; TIME FACTORS;

EID: 0033755092     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001073     Document Type: Article

References (57)

1. Urata H et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
2. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes; physiological and pharmacological implications. J Hypertens 1993; 11 (3): S13-S18.
3. Cushman DW, Cheung HS, Sabo EF, Ondetti MA. Angiotensin converting enzyme inhibitors: evolution of a new class of hypertensive drugs. In: Horowitz ZP (ed). Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications. Urban & Schwartzenberg: Baltimore, MD, 1981, pp 3-25.
4. Lacourciere Y et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-1393.
5. Furukawa Y, Kishimoto S, Nishikawa K. Hypotensive imidatide derivatives. US patent 4,340,598. 1982.
6. Wong PC et al. Non-peptide angiotensin II receptor antagonists. Studies with EXP 9270 and DuP 753. Hypertension 1990; 15: 823-834.
7. Noda M et al. Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new non-peptide All antagonist. Biochem Pharmacol 1993; 46: 311-318.
8. Garcha RS, Sever PS, Hughes AD. Action of AT1-recep-tor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol 1999; 127: 1876-1882.
9. Konishi H, Kuroda S, Inada Y, Fujisawa Y. Novel sub-type of human angiotensin II type 1 receptor: cDNA cloning and expression. Biochem Biophys Bes Com-mun 1994; 199: 467-474.
10. Edwards RM et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist SK& F 108566. Pharmacol Exp Ther 1992; 260: 175-181.
11. Wong PC et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP-3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211-217.
12. Cazaubon C et al. Pharmacological characterization of SR 47436, a new non-peptide ATI sub-type angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826-834.
13. Wienen W et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist BIBR 277. Br J Pharmacol 1993; 110: 245-252.
14. Criscione L et al. Pharmacological profile of valsartan: a potent orally active, nonpeptide antagonist of the angiotensin II ATl-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
15. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-[[2'-(lH-tetrazol-5-yl)biphenyl-4-yl]me-thyl]-lH-benzimidazole-7-carboxylic acid (CV-11974) and its prodrug (+/-)-l-(cyclohexylcarbonyloxy)-ethyl-2-ethoxy-l-[[2'-(lH-tetrazol-5-yl)biphenyl-4-yl]methyl]-lH-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
16. Morsing P, Brandt-Eliasson U, Abrahamsson T. Cande-sartan, an insurmountable antagonist of angiotensin II mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP-3174). Am J Hypertens 1998; 11: 37 [abstract].
17. Ojima M et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319: 137-146.
18. Chiu AT et al. [3H] DUP 753, a highly potent and specific radioligand for the angiotensin-II 1 receptor sub-type. Biochem Biophys Bes Commun 1990; 172: 1195-1202.
19. Abrahamsson T et al. Candesartan causes a long-lasting antagonism of the angiotensin II receptor-mediated contractile effects in isolated vascular preparations: a comparison with losartan and its active metabolite (EXP 3174). Am J Hypertens 1998; 11: 36 [abstract].
20. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacother 1997; 32: 1-29.
21. Belz GG et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan and losartan in healthy human volunteers. J Hum Hypertens 1997; 11 (2): S45-S47.
22. Inada Y et al. Pharmacologic properties of candesartan cilexetil-possible mechanisms of long-acting antihypertensive action. J Hum Hypertens 1999; 13 (1): S75-S80.
23. Belz GG et al. Candesartan cilexetil has the highest pharmacologic potency of various AT1 antagonists-assessed by the Schild regression technique in man. J Hypertens 1999; 17 (3): S66 [abstract].
24. Azizi M et al. Is the differentiation of ATa receptor antagonists feasible in normotensive volunteers? J Hypertens 1997; 15 (4): S116 [abstract].
25. Azizi M, Bernard MC, Menard J. Pharmacokinetics-pharmacodynamic study of renin release during angiotensin II blockade. J Hypertens 1999; 17 (3): S195 [abstract].
26. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998; 56: 847-869.
27. Goa KL, Wagstaff AJ. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-845.
28. Criscione L et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13: 230-250.
29. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Pharmacol 1997; 52: 115-120.
30. Waldmeier F et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xeno-biotica 1997; 27: 59-71.
31. Gillis JC, Markam A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902.
32. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-718.
33. McClellan KJ, Markham A. Telmisartan. Drugs 1998; 56: 1039-1046.
34. Heuer HJ, Schondorfer G, Hogemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (2): S55-S56.
35. Fridman K, Andersson OK, Wysocki M, Friberg P. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 1997; 11 (2): S43-S44.
36. Elmfeldt D et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose-dependent antihypertensive effects. J Hum Hypertens 1997; 11 (2): S49-S53.
37. Pool J et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998; 20: 1106-1114.
38. Reeves RA, Chen-Sheng L, Kassler-Taub K, Pouleur HG. Dose-related efficacy of irbesartan for hypertension. Hypertension 1998; 31: 1311-1316.
39. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the ATa receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
40. Gradman AH et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
41. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59.
42. Lacourcière Y, Asmar R, on behalf of the CHAMP study group. Comparison of the impact of missed doses of candesartan and losartan in ambulatory hypertensive patients. Am J Hypertens 1999; 12: 143a [abstract].
43. Kassler-Taub K et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Hypertens 1998; 11: 445-453.
44. Mallion JM et al. A placebo-controlled comparison between candesartan cilexetil 8 mg and losartan 50 mg monotherapy in patients with essential hypertension using 36-hour ambulatory blood pressure monitoring. Abstract from the 3rd International Symposium on Angiotensin 2 Antagonism, London, March 2000.
45. Hedner T et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am Hypertens 1999; 12: 414-417.
46. Farsang C et al. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10: 80a [abstract].
47. Zanchetti A, Omboni S, Di Biagio C, on behalf of the study group. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (2): S57-S59.
48. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997; 11 (2): S61-S62.
49. Arakawa K et al. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension. A double-blind parallel group-comparison study using enalapril maleate as control drug. Rinsho-Iyaku 1998; 14: 871-918.
50. Malmqvist K, for the Swedish Multicentre Group. In hypertensive women, candesartan cilexetil lowered blood pressure more effectively and is better tolerated than enalapril or a diuretic. Hypertens 1999; 12: 139a [abstract].
51. Mimran A et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesar-tan, with full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203-208.
52. Holwerda NJ et al. Valsart, a new angiotensin II receptor antagonist for the treatment of hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151.
53. Smith DHG, Neutel JM, Morgenstern P. Once-daily tel-misartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-240.
54. Tanser P et al. Candesartan cilexetil is not associated with cough in patients with enalapril-induced cough. Am J Hypertens 1998; 11: 122 [abstract].
55. Belcher G et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11 (2): S85-S89.
56. Mclnnes GT et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (2): S75-S80.
57. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11 (2): S81-S83.